Aflac Q4 2020 Earnings Report
Key Takeaways
Aflac Incorporated reported a strong fourth quarter with total revenues of $5.9 billion, a 5.5% increase from the previous year, and net earnings of $951 million, up 21.6% year-over-year. The results were driven by an increase in net investment gains.
Total revenues increased by 5.5% to $5.9 billion compared to Q4 2019.
Net earnings rose by 21.6% to $951 million, or $1.35 per diluted share.
Adjusted earnings remained nearly flat at $755 million, a 0.1% decrease.
Aflac repurchased $500 million of its common shares during the quarter.
Aflac
Aflac
Aflac Revenue by Segment
Aflac Revenue by Geographic Location
Forward Guidance
Aflac expects pandemic conditions to continue impacting sales results in the United States and Japan through the first half of 2021. The company anticipates a slow return to normal in the second half of the year, expecting to realize the benefits of their 2020 investments.
Positive Outlook
- Marginal sales improvements have been seen on a sequential basis in the last two quarters.
- Continued investment in virtual and digital sales methods and promotion of new products.
- Launched a new medical product in Japan.
- Closed on the acquisition of Zurich North America’s group benefits business.
- Announced the national launch of Aflac Dental & Vision.
Challenges Ahead
- Pandemic conditions continue to impact sales results in the United States and Japan.
- Earned premium and revenues are also affected by the pandemic.
- Uncertain economic conditions persist.
- Claims activity remains a concern in both the U.S. and Japan.
- Need to remain vigilant as the safety and health of everyone with whom we do business is our greatest priority.